# Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients

> **NCT00229138** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 291 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** EC-MPS, Tacrolimus

## Key facts

- **NCT ID:** NCT00229138
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2017-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00229138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00229138, "Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00229138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*